Reata Pharmaceuticals, Inc. RETA announced that it has completed its previously requested pre-new drug application (NDA) meeting with the FDA related to its Friedreich’s ataxia (“FA”) candidate, ...
Reata Pharmaceuticals, Inc. RETA announced that the FDA has asked the company to request a pre-NDA meeting to discuss study data for one of its lead pipeline candidates, omaveloxolone. The regulatory ...
The NHTSA is upping the pressure on Tesla as the regulator asked for more information about the non-disclosure agreement it made Full Self-Driving Beta testers agree to. The government is also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback